表紙
市場調查報告書

乾癬性關節炎 (PsA):流行病學的預測

Psoriatic Arthritis: Epidemiology Forecast to 2028

出版商 GlobalData 商品編碼 920863
出版日期 內容資訊 英文 31 Pages
訂單完成後即時交付
價格
乾癬性關節炎 (PsA):流行病學的預測 Psoriatic Arthritis: Epidemiology Forecast to 2028
出版日期: 2019年11月30日內容資訊: 英文 31 Pages
簡介

乾癬性關節炎 (PsA),是進行性的慢性發炎性關節症,有引起重度的關節損傷和障礙的可能性。 乾癬性關節炎 (PsA)一般人群中很少見,不過,可能影響乾癬患者的最大30%。乾癬性關節炎 (PsA),是表現非特異性症狀的異質性高的疾病,多數情況下診斷變得困難。可是,根據最近確立的CASPAR診斷標準,醫師對出現症狀的患者的診斷得到改善。

本報告提供全球主要7個國家 (美國、法國、德國、義大利、西班牙、英國、日本) 的乾癬性關節炎 (PsA)的發病情形與今後預測相關分析,疾病的特徵和目前患病者的發病情形,今後10年的患病數量的預測值等調查。

第1章 目錄

第2章 乾癬性關節炎 (PsA):摘要整理

第3章 流行病學

  • 疾病的背景
  • 風險要素和合併症
  • 全球趨勢、過去趨勢
  • 預測手法
    • 資訊來源
    • 預測的前提條件與手法
  • 乾癬性關節炎 (PsA的)流行病學的預測
    • 確診發病者數
    • 確診患病人數
    • 確診患病人數:性別
    • 確診患病人數:各年齡
    • 確診患病人數:各重症度
    • 乾癬的PsA已診斷的患病人數
  • 討論
    • 流行病學的預測相關考察
    • 分析的限制
    • 分析的優勢

第4章 附錄

目錄
Product Code: GDHCER225-19

Improvements in identifying and diagnosing Psoriatic Arthritis (PsA), a chronic inflammatory arthropathy, are increasing the number of diagnosed cases in the seven major markets (7MM - The US, France, Germany, Italy, Spain, the UK and Japan). More than 1.4 million adults are expected to be diagnosed with Psoriatic Arthritis (PsA) in the 7MM by 2028, which is up from 1.1 million in 2018.

Psoriatic Arthritis (PsA) is a chronic inflammatory arthropathy that may be progressive in nature and can lead to severe joint damage and disability. The disease is considered to be rare in the general population, but Psoriatic Arthritis (PsA) may affect up to 30% of people with psoriasis. Psoriatic Arthritis (PsA) is a highly heterogeneous disease that may present with unspecific symptoms, often making diagnosis challenging. However, the recently established CASPAR diagnostic criteria is enabling doctors to improve diagnosis of Psoriatic Arthritis (PsA) in patients that show symptoms.

Improving diagnosis of Psoriatic Arthritis (PsA) will continue to allow more cases of the disease to be diagnosed that may have been missed prior to the wide adoption of the CASPAR diagnostic tool. Epidemiologists forecast an increase in the diagnosed prevalent cases of Psoriatic Arthritis (PsA) in the seven major markets (7MM - The US, France, Germany, Italy, Spain, the UK and Japan), from 1,115,840 cases in 2018 to 1,459,664 cases in 2028, in men and women ages 18 years and older. In 2018, GlobalData epidemiologists estimate that 295,328 diagnosed prevalent cases of Psoriatic Arthritis (PsA) were diagnosed as severe across the 7MM, accounting for roughly 26% of all diagnosed cases.

The latest research report, "Psoriatic Arthritis: Epidemiology Forecast to 2028" provides the total number of diagnosed cases or diagnosed prevalent cases in each market. The report's forecast is strengthened by the use of peer-reviewed, country-specific publications, which Studies that supplied diagnosed prevalence based on CASPAR criteria and medical records in countries where CASPAR is predominantly used provide a significant measure of the underlying burden of Psoriatic Arthritis (PsA) in all of the 7MM. Additionally, the use of primary market research data allows for a more real-time analysis of the projected trends in the diagnosis of Psoriatic Arthritis (PsA).

Scope

  • The Psoriatic Arthritis (PsA) Epidemiology Report provides an overview of the risk factors and global trends PsA in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan).
  • This report also includes a 10-year epidemiology forecast for the diagnosed incident cases of PsA, and a 10-year forecast of the diagnosed prevalent cases of PsA segmented by sex and age (beginning at age 18 years and ending at ages 85 years or older) in these markets. Additionally, this report provides an evaluation of the severity of PsA as self-reported by doctors and patients, as well as a forecast of the diagnosed prevalent cases of PsA with psoriasis. The epidemiology model corresponding to this report will provide additional clinically relevant segmentations, including a forecast for the total prevalent (diagnosed and undiagnosed) cases of PsA, diagnosed prevalent cases of PsA by subtype according to Moll and Wright Criteria, and diagnosed prevalent cases with comorbidity.
  • The PsA epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
  • The Epidemiology Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.

Reasons to buy

The PsA Epidemiology series will allow you to -

  • Develop business strategies by understanding the trends shaping and driving the global PsA market.
  • Quantify patient populations in the global PsA market to improve product design, pricing, and launch plans.
  • Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for PsA therapeutics in each of the markets covered.
  • Understand magnitude of PsA population by therapeutic market.

Table of Contents

  • 1.1 List of Tables
  • 1.2 List of Figures

2 Psoriatic Arthritis: Executive Summary

  • 2.1 Catalyst
  • 2.2 Related Reports
  • 2.3 Upcoming Reports

3 Epidemiology

  • 3.1 Disease Background
  • 3.2 Risk Factors and Comorbidities
  • 3.3 Global and Historical Trends
  • 3.4 Forecast Methodology
    • 3.4.1 Sources
    • 3.4.2 Forecast Assumptions and Methods
  • 3.5 Epidemiological Forecast for PsA (2018-2028)
    • 3.5.1 Diagnosed Incident Cases of PsA
    • 3.5.2 Diagnosed Prevalent Cases of PsA
    • 3.5.3 Sex-Specific Diagnosed Prevalent Cases of PsA
    • 3.5.4 Age-Specific Diagnosed Prevalent Cases of PsA
    • 3.5.5 Diagnosed Prevalent Cases of PsA by Severity
    • 3.5.6 Diagnosed Prevalent Cases of PsA with Psoriasis
  • 3.6 Discussion
    • 3.6.1 Epidemiological Forecast Insight
    • 3.6.2 Limitations of the Analysis
    • 3.6.3 Strengths of the Analysis

4 Appendix

  • 4.1 Bibliography
  • 4.2 Primary Research - Prescriber Survey
  • 4.3 About the Authors
    • 4.3.1 Epidemiologist
    • 4.3.2 Reviewers
    • 4.3.3 Global Director of Therapy Analysis and Epidemiology
    • 4.3.4 Global Head and EVP of Healthcare Operations and Strategy
  • 4.4 About GlobalData
  • 4.5 Contact Us
  • 4.6 Disclaimer

List of Tables

  • Table 1: Summary of Newly Added Data Types
  • Table 2: Summary of Updated Data Types
  • Table 3: Risk Factors and Comorbidities for PsA
  • Table 4: High-Prescribing Physicians (non-KOLs) Surveyed, By Country

List of Figures

  • Figure 1: 7MM, Diagnosed Prevalent Cases of PsA, Men and Women, Ages ≥18 Years, 2018 and 2028
  • Figure 2: 7MM, Diagnosed Prevalence of PsA, Men and Women, Ages ≥18 Years, 2008
  • Figure 3: 7MM, Sources Used to Forecast the Diagnosed Incident Cases of PsA
  • Figure 4: 7MM, Sources Used to Forecast the Diagnosed Prevalent Cases of PsA
  • Figure 5: 7MM, Diagnosed Incident Cases of PsA, Men and Women, Ages ≥18 Years
  • Figure 6: 7MM, Diagnosed Prevalent Cases of PsA, Men and Women, Ages ≥18 Years
  • Figure 7: 7MM, Diagnosed Prevalent Cases of PsA by Sex, Ages ≥18 Years, 2018
  • Figure 8: 7MM, Diagnosed Prevalent Cases of PsA by Age, Men and Women, 2018
  • Figure 9: 7MM, Diagnosed Prevalent Cases of PsA by Severity, Men and Women, Ages ≥18 Years, 2018
  • Figure 10: 7MM, Diagnosed Prevalent Cases of PsA with Psoriasis, Men and Women, Ages ≥18 Years